Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

OBJECTIVE: The EXTREME clinical trial revealed that cetuximab plus chemotherapy improved the overall survival time of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) versus chemotherapy alone. The current study examined the cost-effectiveness of cetuximab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Yitian, Dong, Deshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661788/
https://www.ncbi.nlm.nih.gov/pubmed/33204154
http://dx.doi.org/10.2147/CMAR.S272149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661788/
https://www.ncbi.nlm.nih.gov/pubmed/33204154
http://dx.doi.org/10.2147/CMAR.S272149

Ejemplares similares